Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Collagenase clostridium histolyticum is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers as well as to treat Dupuytren's contracture and Peyronie's disease. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease.
- Mechanism
- Curator reviewed · 8 references
Peyronie's disease is a fibrous lesion of the tunica albuginea in the penile tissues. Cellulite is a multifactorial condition resulting in the accumulation of fibrotic dermal septae and the expansion of subcutaneous fat. Dupuytren's contracture is a fibroproliferative disease that results in the fibrous deposition of collagen in the hands, limiting mobility and functionality of the hands. The collagen deposition in the abovementioned conditions is the target of collagenase enzyme therapy.
These enzymes are proteinases acting to hydrolyze collagen's triple-helical conformation, resulting in the lysis of collagen deposits and relief from the necrotic tissue and plaques associated with several conditions. On a molecular level, collagenases cleave polypeptide chains that make up the collagen triple helix structure at various loci, leading to solubilization from the collagen fibril.
- Primary indication
- Collagenase clostridium histolyticum is indicated for the treatment of adults with Dupuytren's contracture with a palpable cord.Curator reviewed · 4 structured indications
- Formula / weight
- C5028H7666N1300O1564S21 · 112023.2 Da
- First approval
- Canada, 2014 · United States, 2006
- Also known as
- Clostridiopeptidase A · Clostridium histolyticum enzymes · Collagenase · collagenase clostridium histolyticum-aaes
- Code names
- AA-4500 · PF-5076985
- Brand names
- Santyl
- Xiaflex
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Collagenase clostridium histolyticum, and which of those have an active Phase 3 trial?